BPC-157 Protects Against Clopidogrel-Induced Stomach Damage Through Multiple Healing Pathways

BPC-157 attenuated clopidogrel-induced gastric ulcer recurrence in rats by inhibiting ER stress-mediated cell death, reducing inflammation, and promoting blood vessel growth via the VEGF-A/AKT/p38 pathway.

Wu, Hailu et al.·Drug design·2020·Moderate Evidenceanimal
RPEP-05203AnimalModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal
Evidence
Moderate Evidence
Sample
N=Not specified (rat study with multiple groups)
Participants
Sprague Dawley rats with acetic acid-induced gastric ulcers treated with clopidogrel

What This Study Found

BPC-157 attenuated clopidogrel-induced gastric mucosa injury by inhibiting ER stress-mediated apoptosis and inflammation while promoting angiogenesis via VEGF-A/VEGFR1-mediated AKT/p38/MAPK signaling. These effects were partially dependent on nitric oxide.

Key Numbers

BPC 157 significantly reduced gastric lesion area; L-NAME partially reversed BPC 157 protection.

How They Did This

Rat model with acetic acid-induced gastric ulcers followed by clopidogrel to trigger recurrence. Groups received clopidogrel alone, with BPC-157, or with L-NAME (NO blocker). Assessed using TUNEL assay, histology, immunohistochemistry, and Western blot for CHOP, VEGF-A, VEGFR1, and eNOS.

Why This Research Matters

Millions of people take clopidogrel for cardiovascular protection but face gastric ulcer risks. BPC-157's multi-pathway gastroprotective mechanism could offer a targeted way to protect the stomach without compromising the blood thinner's cardiovascular benefits.

The Bigger Picture

BPC-157 continues to accumulate evidence as a multi-functional gastroprotective peptide. This study adds clopidogrel-induced injury to the list of gastric conditions where BPC-157 shows preclinical benefit, and importantly elucidates the molecular mechanisms involved.

What This Study Doesn't Tell Us

Animal study in rats — human dosing, safety, and efficacy are not established. The acetic acid ulcer model followed by clopidogrel may not perfectly replicate clinical ulcer recurrence in patients. BPC-157 is not yet approved for clinical use.

Questions This Raises

  • ?Would BPC-157 protect against gastric injury from other antiplatelet or anticoagulant drugs?
  • ?What is the optimal dose and route of BPC-157 for gastroprotection in humans?
  • ?Could BPC-157 be combined with clopidogrel clinically without affecting its antiplatelet efficacy?

Trust & Context

Key Stat:
Multiple pathways BPC-157 acted through ER stress inhibition, anti-inflammation, and angiogenesis promotion simultaneously
Evidence Grade:
Preclinical animal study with detailed mechanistic analysis. Multiple pathways confirmed via Western blot and histology, but no human data available.
Study Age:
Published in 2020. BPC-157 research continues to expand in preclinical settings, though human clinical trials remain limited.
Original Title:
Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157.
Published In:
Drug design, development and therapy, 14, 5599-5610 (2020)
Database ID:
RPEP-05203

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found naturally in human gastric juice. It has shown protective effects on the stomach and other organs in numerous animal studies.

Why does clopidogrel cause stomach problems?

Clopidogrel (Plavix) inhibits platelet aggregation to prevent blood clots, but this same mechanism impairs the stomach lining's ability to repair itself, leading to ulcer recurrence in vulnerable patients.

Read More on RethinkPeptides

Cite This Study

RPEP-05203·https://rethinkpeptides.com/research/RPEP-05203

APA

Wu, Hailu; Wei, Ming; Li, Nan; Lu, Qin; Shrestha, Sachin Mulmi; Tan, Jiacheng; Zhang, Zhenyu; Wu, Guoqiu; Shi, Ruihua. (2020). Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157.. Drug design, development and therapy, 14, 5599-5610. https://doi.org/10.2147/DDDT.S284163

MLA

Wu, Hailu, et al. "Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157.." Drug design, 2020. https://doi.org/10.2147/DDDT.S284163

RethinkPeptides

RethinkPeptides Research Database. "Clopidogrel-Induced Gastric Injury in Rats is Attenuated by ..." RPEP-05203. Retrieved from https://rethinkpeptides.com/research/wu-2020-clopidogrelinduced-gastric-injury-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.